Want to see ANIP full AI Analyst Report?
ANIP Stock Chart & Stats
$77.65
$0.72(0.93%)
At close: 4:00 PM EDT
$77.65
$0.72(0.93%)
Day’s Range― - ―
52-Week Range$70.15 - $99.50
Previous Close$78.37
Volume352.39K
Average Volume (3M)301.85K
Market Cap
$1.70B
Enterprise Value$2.05K
Total Cash (Recent Filing)$360.21M
Total Debt (Recent Filing)$330.34M
Price to Earnings (P/E)15.6
Beta0.48
Next Earnings
Nov 11, 2026EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.83
Shares Outstanding22,734,617
10 Day Avg. Volume270,360
30 Day Avg. Volume301,853
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.93
Price to Sales (P/S)1.79
P/FCF Ratio10.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$110.83Price Target Upside42.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)9.29
Revenue Forecast (FY)$1.11B
Bulls Say, Bears Say
Bulls Say
Accelerating Flagship Product GrowthSustained high-single/low-double-digit quarters and a multi‑year guide for Cortrophin create a durable revenue engine. With broad specialty adoption and a dedicated gout sales expansion, Cortrophin can meaningfully drive company top‑line scale and predictable branded cash flows over coming years.
Improving Leverage And ROEMaterial deleveraging versus prior years and strengthening ROE reflect improved financial stability and capital efficiency. Lower leverage increases flexibility for reinvestment, M&A, buybacks or R&D, reducing solvency risk and supporting multi‑quarter strategic plans.
Diversified Manufacturing And Generics ExecutionA steady cadence of generics launches plus in‑house manufacturing provides a repeatable cash baseline and margin capture. Balanced branded and generics streams reduce concentration risk, smooth revenue cyclicality, and sustain cash generation as new launches and filings continue driving volume.
Bears Say
Historical Earnings And Cash-flow VolatilityIntermittent loss years and recent negative FCF growth indicate sensitivity to timing, one‑offs, or working capital swings. That variability undermines predictability for capital allocation and could constrain investment or returns if adverse operational events recur over the next several quarters.
Margin Pressure From Rising Cost Of Sales And SG&ARapid commercial expansion increases fixed selling costs while cost of goods rose materially. If revenue ramp lags or mix shifts unfavorably, margin compression could persist for multiple quarters, pressuring operating leverage and requiring sustained higher sales productivity to restore prior margins.
Revenue‑mix Risk From Gout CommercializationShifting growth toward a gout population that uses fewer vials per script reduces revenue per patient and can increase discounting and gross‑to‑net compression. Over time, substantial mix change could cap ASP expansion and limit incremental profitability from volume growth.
ANI Pharmaceuticals News
ANIP FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Ani Pharmaceuticals lowest stock price was $70.15 and its highest was $99.50 in the past 12 months.
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is $1.70B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on Aug 07, 2026. The company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.043 by $0.167.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 2.2.
How many shares outstanding does Ani Pharmaceuticals have?
Ani Pharmaceuticals has 22,734,617 shares outstanding.
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $2.21 in its last earnings report, beating expectations of $2.043. Following the earnings report the stock price went down -5.301%.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in ANIP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.83 (42.73% Upside)
$110.83 (42.73% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 769.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Company Deck
ANIP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution with record Q2 revenue, record adjusted EBITDA, robust Cortrophin momentum, a major sales force expansion, continued generics execution and a healthy balance sheet. Near-term headwinds include timing-related adjustments (modest Cortrophin guidance revision), higher cost of sales and increased SG&A from the gout expansion, and a Q3 EBITDA sequential dip tied to milestone timing and fully loaded expansion costs. Management emphasizes continued confidence in multi-year Cortrophin growth and reaffirmed full-year company guidance, indicating that the positives (growth, margin expansion outlook, cash generation and strategic progress) meaningfully outweigh the short-term operational and timing challenges.View all ANIP earnings summariesANIP Stock 12 Month Forecast
Average Price Target
$110.83
▲(42.73% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―
Ownership Overview
7.92% Insiders
19.67% Mutual Funds
11.31% Other Institutional Investors
35.92% Public Companies and
Individual Investors